Exelixis (EXEL) Stock Forecast, Price Target & Predictions
EXEL Stock Forecast
Exelixis stock forecast is as follows: an average price target of $30.50 (represents a -11.47% downside from EXEL’s last price of $34.45) and a rating consensus of 'Buy', based on 16 wall street analysts offering a 1-year stock forecast.
EXEL Price Target
The average price target for Exelixis (EXEL) is $30.50 based on 1-year price targets from 16 Wall Street analysts in the past 3 months, with a price target range of $38.00 to $18.00. This represents a potential -11.47% downside from EXEL's last price of $34.45.
EXEL Analyst Ratings
According to 16 Wall Street analysts, Exelixis's rating consensus is 'Buy'. The analyst rating breakdown for EXEL stock is 0 'Strong Buy' (0.00%), 13 'Buy' (81.25%), 2 'Hold' (12.50%), 1 'Sell' (6.25%), and 0 'Strong Sell' (0.00%).
Exelixis Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 30, 2024 | Etzer Darout | BMO Capital | $36.00 | $32.56 | 10.57% | 4.50% |
| Oct 30, 2024 | Asthika Goonewardene | Truist Financial | $38.00 | $28.73 | 32.27% | 10.30% |
| Oct 30, 2024 | Joseph Catanzaro | Piper Sandler | $36.00 | $28.73 | 25.30% | 4.50% |
| Oct 30, 2024 | David Lebowitz | Citigroup | $38.00 | $28.73 | 32.27% | 10.30% |
| Oct 16, 2024 | Christopher Liu | Leerink Partners | $28.50 | $28.50 | - | -17.27% |
| Oct 16, 2024 | Kennen MacKay | RBC Capital | $34.00 | $28.50 | 19.30% | -1.31% |
| Oct 16, 2024 | Chris Shibutani | Goldman Sachs | $18.00 | $28.50 | -36.84% | -47.75% |
| Oct 15, 2024 | Akash Tewari | Jefferies | $33.00 | $28.80 | 14.60% | -4.21% |
| Oct 15, 2024 | Jeffrey Hung | Morgan Stanley | $30.00 | $28.50 | 5.26% | -12.92% |
| Oct 14, 2024 | Asthika Goonewardene | Truist Financial | $33.00 | $26.24 | 25.76% | -4.21% |
The latest Exelixis stock forecast, released on Oct 30, 2024 by Etzer Darout from BMO Capital, set a price target of $36.00, which represents a 10.57% increase from the stock price at the time of the forecast ($32.56), and a 4.50% increase from EXEL last price ($34.45).
Exelixis Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 4 | 15 | 20 |
| Avg Price Target | $37.00 | $31.10 | $30.48 |
| Last Closing Price | $34.45 | $34.45 | $34.45 |
| Upside/Downside | 7.40% | -9.72% | -11.52% |
In the current month, the average price target of Exelixis stock is $37.00, according to 4 Wall Street analysts offering twelve months forecast. The average price target represents a 7.40% increase as opposed to Exelixis's last price of $34.45. This month's average price target is up 18.97% compared to last quarter, and up 21.39% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 30, 2024 | Guggenheim | Buy | Buy | Hold |
| Oct 30, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Oct 21, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Oct 16, 2024 | Leerink Partners | Market Perform | Market Perform | Hold |
| Oct 16, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Oct 16, 2024 | Goldman Sachs | Sell | Sell | Hold |
| Oct 15, 2024 | Jefferies | Buy | Buy | Hold |
| Oct 15, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 15, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Oct 15, 2024 | Morgan Stanley | Positive | Positive | Hold |
Exelixis's last stock rating was published by Guggenheim on Oct 30, 2024. The company gave EXEL a "Buy" rating, the same as its previous rate.
Exelixis Financial Forecast
Exelixis Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $479.65M | $471.92M | $469.85M | $408.79M | $423.92M | $411.74M | $419.43M | $355.98M | $451.14M | $328.42M | $385.18M | $270.23M | $270.05M | $231.09M |
| Avg Forecast | $754.20M | $727.10M | $690.20M | $613.90M | $605.10M | $572.90M | $552.60M | $508.00M | $575.43M | $556.12M | $527.64M | $496.68M | $556.45M | $490.31M | $465.47M | $461.04M | $480.33M | $473.48M | $446.29M | $422.66M | $417.61M | $403.47M | $391.03M | $374.45M | $355.78M | $358.58M | $300.03M | $266.56M | $270.00M | $214.67M |
| High Forecast | $783.53M | $755.38M | $717.04M | $637.77M | $628.63M | $595.18M | $574.09M | $527.76M | $597.80M | $577.74M | $548.16M | $511.35M | $585.26M | $491.49M | $465.47M | $461.04M | $514.18M | $497.32M | $463.65M | $439.09M | $433.85M | $403.47M | $391.03M | $374.45M | $355.78M | $358.58M | $300.03M | $266.56M | $270.00M | $214.67M |
| Low Forecast | $716.32M | $690.58M | $655.53M | $583.06M | $574.71M | $544.12M | $524.84M | $482.48M | $546.52M | $528.18M | $501.13M | $482.12M | $502.25M | $489.12M | $465.47M | $461.04M | $449.25M | $446.19M | $423.87M | $401.43M | $396.63M | $403.47M | $391.03M | $374.45M | $355.78M | $358.58M | $300.03M | $266.56M | $270.00M | $214.67M |
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 13 | 6 | 6 | 6 | 10 | 15 | 7 | 7 | 10 | 11 | 11 | 11 | 7 | 7 | 7 | 7 | 7 | 13 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 1.00% | 1.05% | 0.97% | 1.02% | 1.02% | 1.07% | 0.95% | 1.27% | 0.92% | 1.28% | 1.01% | 1.00% | 1.08% |
Exelixis's average Quarter revenue forecast for Mar 24 based on 6 analysts is $461.04M, with a low forecast of $461.04M, and a high forecast of $461.04M. EXEL's average Quarter revenue forecast represents a -3.88% decrease compared to the company's last Quarter revenue of $479.65M (Dec 23).
Exelixis EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 13 | 6 | 6 | 6 | 10 | 15 | 7 | 7 | 10 | 11 | 11 | 11 | 7 | 7 | 7 | 7 | 7 | 13 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $88.31M | $-17.58M | $77.85M | $28.83M | $-48.08M | $88.28M | $88.48M | $83.24M | $119.95M | $58.06M | $128.56M | $1.21M | $30.54M | $-35.67M |
| Avg Forecast | $142.99M | $137.85M | $130.85M | $116.39M | $114.72M | $108.61M | $104.77M | $96.31M | $109.09M | $105.43M | $100.03M | $94.16M | $105.50M | $92.96M | $88.25M | $70.06M | $91.06M | $89.76M | $84.61M | $63.69M | $254.47M | $74.68M | $72.38M | $50.35M | $65.85M | $66.37M | $55.53M | $1.82M | $49.98M | $39.73M |
| High Forecast | $148.55M | $143.21M | $135.94M | $120.91M | $119.18M | $112.84M | $108.84M | $100.06M | $113.34M | $109.53M | $103.92M | $96.95M | $110.96M | $93.18M | $88.25M | $84.07M | $97.48M | $94.29M | $87.90M | $76.43M | $305.36M | $74.68M | $72.38M | $60.42M | $65.85M | $66.37M | $55.53M | $2.18M | $49.98M | $39.73M |
| Low Forecast | $135.80M | $130.92M | $124.28M | $110.54M | $108.96M | $103.16M | $99.50M | $91.47M | $103.61M | $100.14M | $95.01M | $91.40M | $95.22M | $92.73M | $88.25M | $56.05M | $85.17M | $84.59M | $80.36M | $50.95M | $203.58M | $74.68M | $72.38M | $40.28M | $65.85M | $66.37M | $55.53M | $1.45M | $49.98M | $39.73M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.97% | -0.20% | 0.92% | 0.45% | -0.19% | 1.18% | 1.22% | 1.65% | 1.82% | 0.87% | 2.31% | 0.67% | 0.61% | -0.90% |
6 analysts predict EXEL's average Quarter EBITDA for Mar 24 to be $70.06M, with a high of $84.07M and a low of $56.05M. This is -20.67% lower than Exelixis's previous annual EBITDA (Dec 23) of $88.31M.
Exelixis Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 13 | 6 | 6 | 6 | 10 | 15 | 7 | 7 | 10 | 11 | 11 | 11 | 7 | 7 | 7 | 7 | 7 | 13 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $85.52M | $1.04M | $81.18M | $40.03M | $-30.17M | $73.21M | $70.67M | $68.57M | $95.17M | $38.20M | $96.09M | $1.60M | $28.39M | $-32.04M |
| Avg Forecast | - | - | - | - | $198.23M | $185.64M | $173.14M | $148.74M | $123.48M | $126.88M | $110.77M | $98.11M | $111.71M | $98.90M | $90.31M | $52.48M | $66.45M | $28.54M | $44.89M | $47.71M | $201.89M | $56.31M | $57.82M | $37.72M | $17.93M | $57.46M | $17.88M | $2.40M | $16.84M | $2.94M |
| High Forecast | - | - | - | - | $208.26M | $195.03M | $181.89M | $156.26M | $129.73M | $133.30M | $116.37M | $107.93M | $140.85M | $99.00M | $90.33M | $62.98M | $77.17M | $51.38M | $47.16M | $57.25M | $242.27M | $56.31M | $57.82M | $45.26M | $17.93M | $57.46M | $17.88M | $2.88M | $16.84M | $2.94M |
| Low Forecast | - | - | - | - | $185.29M | $173.52M | $161.83M | $139.03M | $115.42M | $118.60M | $103.54M | $85.85M | $60.71M | $98.81M | $90.29M | $41.98M | $53.59M | $-24.74M | $41.96M | $38.17M | $161.51M | $56.31M | $57.82M | $30.17M | $17.93M | $57.46M | $17.88M | $1.92M | $16.84M | $2.94M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.29% | 0.04% | 1.81% | 0.84% | -0.15% | 1.30% | 1.22% | 1.82% | 5.31% | 0.66% | 5.37% | 0.67% | 1.69% | -10.90% |
Exelixis's average Quarter net income forecast for Mar 24 is $52.48M, with a range of $41.98M to $62.98M. EXEL's average Quarter net income forecast represents a -38.63% decrease compared to the company's last Quarter net income of $85.52M (Dec 23).
Exelixis SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 13 | 6 | 6 | 6 | 10 | 15 | 7 | 7 | 10 | 11 | 11 | 11 | 7 | 7 | 7 | 7 | 7 | 13 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $131.44M | $138.14M | $141.72M | $131.40M | $119.25M | $114.98M | $122.76M | $102.86M | $99.31M | $101.56M | $98.50M | $102.35M | $82.44M | $88.19M |
| Avg Forecast | $210.39M | $202.83M | $192.54M | $171.25M | $168.80M | $159.82M | $154.15M | $141.71M | $160.52M | $155.14M | $147.19M | $138.55M | $155.23M | $136.78M | $129.85M | $78.72M | $133.99M | $132.08M | $124.50M | $71.57M | $210.68M | $112.55M | $109.08M | $56.57M | $99.25M | $100.03M | $83.70M | $153.53M | $75.32M | $59.88M |
| High Forecast | $218.58M | $210.72M | $200.03M | $177.91M | $175.36M | $166.03M | $160.15M | $147.22M | $166.76M | $161.17M | $152.91M | $142.65M | $163.26M | $137.11M | $129.85M | $94.47M | $143.44M | $138.73M | $129.34M | $85.88M | $252.82M | $112.55M | $109.08M | $67.89M | $99.25M | $100.03M | $83.70M | $184.23M | $75.32M | $59.88M |
| Low Forecast | $199.83M | $192.65M | $182.87M | $162.65M | $160.32M | $151.79M | $146.41M | $134.59M | $152.46M | $147.34M | $139.80M | $134.49M | $140.11M | $136.45M | $129.85M | $62.98M | $125.32M | $124.47M | $118.24M | $57.25M | $168.54M | $112.55M | $109.08M | $45.26M | $99.25M | $100.03M | $83.70M | $122.82M | $75.32M | $59.88M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.98% | 1.05% | 1.14% | 1.84% | 0.57% | 1.02% | 1.13% | 1.82% | 1.00% | 1.02% | 1.18% | 0.67% | 1.09% | 1.47% |
Exelixis's average Quarter SG&A projection for Mar 24 is $78.72M, based on 6 Wall Street analysts, with a range of $62.98M to $94.47M. The forecast indicates a -40.11% fall compared to EXEL last annual SG&A of $131.44M (Dec 23).
Exelixis EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 13 | 6 | 6 | 6 | 10 | 15 | 7 | 7 | 10 | 11 | 11 | 11 | 7 | 7 | 7 | 7 | 7 | 13 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.25 | $0.12 | $-0.09 | $0.23 | $0.22 | $0.21 | $0.30 | $0.12 | $0.31 | $0.01 | $0.09 | $-0.10 |
| Avg Forecast | - | - | - | - | $0.68 | $0.64 | $0.59 | $0.51 | $0.42 | $0.44 | $0.38 | $0.34 | $0.38 | $0.34 | $0.31 | $0.22 | $0.23 | $0.10 | $0.15 | $0.16 | $-0.11 | $0.19 | $0.20 | $0.14 | $0.06 | $0.20 | $0.06 | $0.03 | $0.06 | $0.01 |
| High Forecast | - | - | - | - | $0.71 | $0.67 | $0.62 | $0.54 | $0.45 | $0.46 | $0.40 | $0.37 | $0.48 | $0.34 | $0.31 | $0.23 | $0.26 | $0.18 | $0.16 | $0.17 | $-0.10 | $0.19 | $0.20 | $0.14 | $0.06 | $0.20 | $0.06 | $0.03 | $0.06 | $0.01 |
| Low Forecast | - | - | - | - | $0.64 | $0.60 | $0.56 | $0.48 | $0.40 | $0.41 | $0.36 | $0.29 | $0.21 | $0.34 | $0.31 | $0.22 | $0.18 | $-0.08 | $0.14 | $0.15 | $-0.12 | $0.19 | $0.20 | $0.14 | $0.06 | $0.20 | $0.06 | $0.03 | $0.06 | $0.01 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.03% | 1.62% | 0.75% | 0.84% | 1.20% | 1.12% | 1.48% | 4.92% | 0.61% | 5.10% | 0.17% | 1.57% | -10.00% |
According to 10 Wall Street analysts, Exelixis's projected average Quarter EPS for Dec 23 is $0.23, with a low estimate of $0.18 and a high estimate of $0.26. This represents a 6808.18% increase compared to EXEL previous annual EPS of - (Sep 23).
Exelixis Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BTAI | BioXcel Therapeutics | $0.57 | $12.00 | 2005.26% | Buy |
| XFOR | X4 Pharmaceuticals | $0.40 | $3.67 | 817.50% | Buy |
| KOD | Kodiak Sciences | $5.53 | $31.60 | 471.43% | Buy |
| PDSB | PDS Bio | $2.01 | $9.00 | 347.76% | Buy |
| VKTX | Viking Therapeutics | $49.58 | $102.40 | 106.53% | Buy |
| SRPT | Sarepta Therapeutics | $104.54 | $169.06 | 61.72% | Buy |
| BMRN | BioMarin Pharmaceutical | $63.42 | $101.70 | 60.36% | Buy |
| HALO | Halozyme Therapeutics | $45.65 | $57.00 | 24.86% | Buy |
| PTCT | PTC Therapeutics | $39.23 | $46.50 | 18.53% | Hold |
| KRYS | Krystal Biotech | $170.74 | $191.00 | 11.87% | Buy |
| MDGL | Madrigal Pharmaceuticals | $288.58 | $315.75 | 9.42% | Buy |
| ALNY | Alnylam Pharmaceuticals | $235.56 | $254.21 | 7.92% | Buy |
| TGTX | TG Therapeutics | $29.54 | $27.60 | -6.57% | Buy |
| EXEL | Exelixis | $34.45 | $30.50 | -11.47% | Buy |